5-year actuarial tumor control rate between 47% and 80% following one procedure. 6, 18, 24, 28, 36, 38, 40, 43 Traditionally, the therapeutic approach for chordomas has relied upon aggressive resection, which in the case of a skull base tumor is often precluded by the lesion's proximity to the cranial nerves and brainstem. Proton-beam radiation therapy has been demonstrated to be a valuable adjuvant modality that improves local tumor control. 12, 24 Medical therapy, however, remains suboptimal as the tumor is refractory to cytotoxic chemotherapy. 8 The choice of surgical procedure, extent of resection, and the modality and dose of radiotherapy may have a significant influence on the morbidity experienced by the patient. Improving patient quality of life during and after treatment is a primary end point underlying clinical decision making and the development of optimal treatment regimens for patients with skull base tumors. 23 The success of this process is contingent upon the identification of determinants of patient-reported health-related quality of life (HRQOL) outcomes that remain largely unknown in patients with chordoma. 2, [20] [21] [22] 29, 30, 37 In this cross-sectional study, we surveyed a cohort of patients to determine the HRQOL of those with skull base chordomas, and we compared findings in these cases to those in the general US population and to those in patients with other disease states. We also sought to determine which demographic or clinical factors most significantly affect quality of life in patients with chordomas. The results of our study identify key predictors of HRQOL that will facilitate the development of optimal clinical management algorithms.
Methods

Patient Recruitment
Ethical approval for this study was obtained from the St. Michael's Hospital Research Ethics Board. Participants were recruited from an international internet-based support group for chordoma. As of 2010, the online community consisted of more than 190 members including patients, friends, or family affected by chordoma or chondrosarcoma. The support group members use email and message boards for sharing resources, information, and experiences with each other. All members of the support network were invited to participate through an email containing a letter of information and a URL link to the survey. A general invitation to participate with a URL link was also advertised on support website message boards. Implied consent was obtained from study subjects who responded to the invitation to participate. Participants were considered eligible if they had a confirmed diagnosis of primary chordoma of the skull base. Patients with other skull base lesions or tumor in the mobile spine or sacrum were excluded.
Instruments
Functional status was assessed using 2 validated scales-Karnofsky Performance Scale (KPS) 51 and Glasgow Outcome Scale Extended (GOSE). 58 The KPS classifies functional impairment by scoring responses from 0 (death) to 100 (normal activity). The GOSE classifies function into 1 of 8 categories with lower scores indicating a worse disability (1, To determine states of anxiety and depression, the Patient Health Questions-9 (PHQ-9) instrument was administered. 32 Based on participant responses to 9 questions, the severity of depression can be categorized into minimal (a score of 1-4), mild (a score of 5-9), moderate (a score of [10] [11] [12] [13] [14] , moderately severe (a score of [15] [16] [17] [18] [19] , and severe (a score of [20] [21] [22] [23] [24] [25] [26] [27] . The 22-item Zarit Burden Interview (ZBI) was used to measure the level of subjective burden among caregivers. 4 Scores range from 0 to 88 and increase with severity of burden.
Demographic and clinical variables were obtained through self-administered online patient and caregiver questionnaires. The instrument requested information on patient age, age at diagnosis, smoking, alcohol use, employment, marital status, annual income (in Canadian dollars), geographic location, tumor type, comorbid conditions, medication, neurological symptoms and signs, treatment modalities, duration of hospital stay, and radiation dose. The complete questionnaire is reproduced in table in Appendix 1.
Data Analysis
All scales were scored according to their published methodology. See Appendix 2 for a detailed outline of each outcome scale and its interpretation. Shapiro-Wilk testing was used to test for normally distributed data. Norm-based SF-36 scores in our sample were compared with those of the general US population 35 using a 1-tailed Student t-test with p < 0.05 set as an indication of statistical significance. To compare SF-36 PCS and MCS scores observed in our study to those observed in patients with other disease states, we searched PubMed for studies reporting SF-36 PCS and MCS scores. The following conditions were selected for comparison: spinal cord injury, ables and functional or HRQOL outcomes. A univariate significance p < 0.05 was set a priori, and only significant variables in the univariate analysis were considered for multivariate linear regression. Correlations between continuous variables were tested using 2-tailed Spearman's Rho with p < 0.05 set as an indication of statistical significance. Multiple linear regression modeling was used to determine factors associated with the SF-36 PCS and MCS scores. A backward-elimination method was used for both the PCS and MCS linear regression models. All univariate, correlation, and multiple linear regression analyses were performed using IBM SPSS Statistics v.21.
Results
Study Population Characteristics
A total of 88 participants consented and attempted the study questionnaire. Responses from 3 participants were excluded because their tumors were located in the sacrum and those from another 2 participants were also excluded because their survey responses were inappropriate. Therefore, the study consisted of 83 unique individuals in whom skull base chordomas had been diagnosed. The demographic and clinical characteristics of the study participants are summarized in Tables 1 and 2 , respectively. More than half of respondents (58%) lived in North America, and almost all (90%) lived at home at the time the questionnaire was answered. Of the remaining participants, 2 lived in South America, 10 in Europe, 7 in Australia or New Zealand, and 6 in Asia. The majority of survey participants were between 51 and 60 years old. The age at diagnosis showed a bimodal distribution, with peaks at less than 20 years old and 41-50 years old. Approximately 83% of participants attained greater or equal to a secondary level of education; however, only 51% of respondents were employed at the time of the survey.
The majority of participants (80.7%) reported fewer than 3 comorbidities. A large proportion of respondents (54.2%) had a family history of cancer. Over half of the participants showed good functional status. Figure 1 shows KPS and GOSE score histograms for the study sample, demonstrating that 67.5% of participants had a KPS score greater than 70% and that 65% had a GOSE score greater than 5. The median KPS score was 90 (mean 82; SD 17; range 10-100; IQR 10; n = 73) and the median GOSE score was 8 (range 2-8; IQR 3; n = 73). The most common presenting symptoms were headache (54%) and diplopia (46%), and the most common clinical sign was cranial nerve deficit (74%).
A summary of the therapeutic interventions participants underwent is provided in Table 3 . Approximately half (53.2%) of the participants had never been prescribed corticosteroids (Table 2 ). Of the remaining 37 patients, 11 were currently on corticosteroids while 26 had ceased corticosteroid use for greater than 6 months. The majority of patients (87.9%) underwent surgery. Surgical intervention usually involved an oral or transsphenoidal approach solely or in addition to craniotomy. The length of postoperative hospitalization varied from less than 3 days to greater than 4 weeks. Approximately 67% of surgically treated patients were also treated with adjuvant radiotherapy. The most common form of radiotherapy was proton beam, which was used in 21 of 34 patients.
Health-Related Quality of Life
The SF-36 subscale, PCS, and MCS scores reported are most representative of patients after surgical intervention and radiation treatment. Despite only about one-third of participants having a limited functional status, both physical health and mental health SF-36 subscale scores were significantly lower in the study population compared with SF-36 normative data for the US population (Fig. 2) . The mean SF-36 PCS score was 43.6 (SD 11.8, n = 74) and the mean MCS score was 44.2 (SD 12.6, n 74) for the study cohort, and these were comparable to PCS and MCS scores for patients with low-grade glioma or oral cancer survivors (Fig. 3) . No correlation was found between current age, age at symptom presentation, or age at diagnosis and SF-36 subscores or summary component scores (Table 4) . Both KPS and GOSE score correlated positively with PCS and MCS scores ( Table 4 ). The degree of depression, as measured by PHQ-9, correlated negatively with MCS scores (Spearman's Rho = -0.674, p < 0.001) and did not correlate with PCS scores (Spearman's Rho = -0.186, p = 0.114). Among social factors, smoking was associated with a worse MCS score (p = 0.024), married social status was associated with a worse PCS score (p = 0.045), and nonretirement status was associated with a worse MCS score (p = 0.047). The disease-related factors at presentation associated with a worse PCS score included the presence of motor deficit (p = 0.008), sensory deficit (p = 0.008), and bowel/bladder dysfunction (p = 0.01). Only headache (p = 0.048) and neck pain (p = 0.026) at presentation were adversely associated with the MCS score.
The disease-related factors at the time of questionnaire administration that were associated with a worse PCS score were headache (p = 0.031), cranial nerve deficit (p = 0.025), motor deficit (p < 0.001), sensory deficit (p = 0.027), gait disturbance (p = 0.035), and bowel/bladder dysfunction (p = 0.008). No neurological symptoms or signs at the time of questionnaire administration were associated with the MCS score. Surgical intervention or radiotherapy was not associated with the PCS or MCS score; however, surgery approached statistical significance (p = 0.088) for the PCS score. The use of corticosteroids had a significant association with a worse PCS (p = 0.008) and MCS (p = 0.005) score. In addition, the use of pain medication, which is presumed to be related to tumor-associated pain, was correlated with a worse PCS score (p = 0.001) but not with MCS score. Values for PCS and MCS in relation to categorical demographic and clinical variables are reported in the table in Appendix 3. 
Depression
Depression was measured in our study population using the PHQ-9 instrument. The median PHQ-9 score was 5 (IQR 8, range 0-27). The scores did not follow a normal distribution (Fig. 4 upper) . Moderate to severe depression (PHQ-9 score ≥ 10; 88% sensitivity and 88% specificity for predicting major depression 32 ) was observed in 29% of respondents (n = 73). Sensory deficit at presentation, but no other clinical sign or symptom, was associated with a higher PHQ-9 score. Depression level was negatively correlated with KPS score (Spearman's Rho -0.507, p < 0.001) and GOSE (Spearman's Rho -0.436, p < 0.001) as well as with SF-36 MCS score (Spearman's Rho -0.674, p < 0.001).
Caregiver Burden
The ZBI was completed by 24 caregivers. The median ZBI score was 12 (range 0-43). Caregiver burden levels did not fit a normal distribution (Fig. 4 lower) . None of the demographic, disease-related, or treatment-related factors tested was associated with ZBI scores.
Predictors of HRQOL
Linear regression analysis was performed to determine which clinical factors could account for the variability observed in physical health-related quality of life (as measured using the SF-36 PCS score) or mental healthrelated quality of life (as measured using the SF-36 MCS score). Four variables (sensory deficit at presentation, current bowel or bladder dysfunction, use of pain medication, and use of corticosteroids) were significant determinants of the PCS score (adjusted R 2 = 0.349, p < 0.001; Table 5 ). Higher physical health-related quality of life is predicted in patients with no sensory deficit at presentation, no bowel or bladder dysfunction, no pain medication use, and no history of requiring corticosteroids. The coefficient of variation for the PCS regression analysis was 20%. On multivariate analysis, the PHQ-9 score was the only significant predictor of MCS (predicted MCS score = 52.88-1.32 × PHQ-9 score; linear regression adjusted R 2 = 0.432, p < 0.0001). The coefficient of variation for the MCS regression analysis was 21%.
Discussion
To our knowledge, ours was the first investigation of the HRQOL in community-dwelling individuals with previously diagnosed skull base chordoma. Our study data suggest that HRQOL in chordoma patients is most affected by the following: 1) neurological deficits (sensory deficit and bowel/bladder dysfunction), 2) pain medication use, 3) corticosteroid use, and 4) levels of depression as scored by PHQ-9.
Compared with cases in the available literature, skull base chordoma patients had a similar HRQOL profile as low-grade glioma and oral cancer survivors, as determined by SF-36 scores. 1, 17 Skull base chordoma patients were also shown to have better physical functioning-related quality of life than patients with spinal cord injury or stroke. 19 This finding should not be interpreted to mean that chordoma patients are not challenged by their physical impairment in activities of daily living. (In fact, the most frequent neurological deficit in our study was cranial nerve deficit.) Rather, this finding highlights two important considerations. First, it demonstrates that although there are a variety of instruments available to estimate HRQOL, each varies widely in its scope and, if used individually, may be limited in its application. For example, the ability of SF-36 to measure the extent of quality of life impairment due to cranial nerve deficit may not be optimal since the SF-36 does not include the content areas of eating, communication, self-esteem, and adequacy of sleep. 56 Second, skull base chordoma patients suffer from a a unique disease process in which the nature of their condition simultaneously resembles that of a chronic neurodegenerative illness while also sharing attributes with other oncological conditions. Therefore, a meaningful evaluation of HRQOL must be multidimensional and involve the use of multiple tools to retrieve information pertaining to the physical, emotional, social, and economic aspects of a patient's life. 59 Our study documented frequent cranial nerve palsies in patients with chordoma, and the most common was diplopia. Neurological symptoms such as headache, 63 diplopia, 33 and dizziness 31, 39 that are common in patients with skull base chordomas have been associated with anxiety and depression. We did not observe an association between cranial nerve deficit and depression as measured by PHQ-9 score. In our study cohort, the rate of moderate to severe depression measured by PHQ-9 was almost five times higher than that in primary care patients. 32 This is in keeping with reports of depression symptoms after surgery in patients with anterior skull base tumors 42 and in patients with head and neck cancer. 13 Although patients with headache had a higher mean PHQ-9 than those without headache, the p value (p = 0.075) did not meet the a priori cutoff for statistical significance. Sensory deficit at presentation and overall functional capacity at the time of survey completion were the only determinants of depression severity in our study cohort. In comparison, depression symptoms in patients with cervical spondylotic myelopathy are associated with a reduction in mobility but not sensory deficit. 54 Mood may be more greatly affected by the presence of a sensory deficit in skull base chordoma patients who are in a younger patient group than those with spondylotic myelopathy. This is suggested by the findings in stroke patients in whom greater depression is associated with younger age. 46 A proactive approach to screening for mood changes in patients with skull base chordoma is encouraged in the clinic given the high prevalence of depression and its negative impact on quality of life discovered in the cohort of patients presented here.
In our study cohort, neurological symptoms such as sensory deficit, gait disturbance, and bowel/bladder dysfunction had a significant impact on the PCS score but not the MCS score of the SF-36. The neurological deficits most predictive of poor quality of life were sensory deficit at presentation and bowel or bladder dysfunction in the posttreatment period. This information is valuable for identifying patients who may be in need of additional physical therapy or occupational therapy support at home to improve their physical health-related quality of life. Furthermore, avoiding interventions that could exacerbate gait disturbance such as retraction of the cerebellum or brainstem, destruction of the semicircular canals, and manipulation of the eighth cranial nerve should be considered. Ideally, surgical intervention before the tumor bulk produces ataxia, pyramidal weakness, sensory deficits, or bowel/bladder dysfunction may further enhance quality of life in these patients.
When we examined treatment factors that could potentially affect quality of life, we were not able to detect an effect of radiation therapy or surgery. However, the analysis of these two factors is confounded by the fact that the majority of patients had both treatment modalities such that the comparison group is small. Reduction in quality of life has been previously reported for patients with anterior skull base tumors after radiation therapy. 22, 42 The effect of resection on quality of life in patients with anterior skull base tumor varies according to the underlying diagnosis and the surgical approach; however, none of these studies has included more than two chordoma patients. 20, 22, 42 It is possible that we did not observe an effect of surgery or radiotherapy on HRQOL because the time from treatment to study participation was not constant for all patients. In addition, there was no baseline preoperative assessment of HRQOL for comparison.
A surprising finding in our study was the strong association between corticosteroid use/pain medication use and HRQOL. We speculate that the use of corticosteroids may reflect a greater burden of disease so that the effect on HRQOL is a product of increasing symptoms related to tumor growth. This hypothesis remains to be directly tested, as we did not have clinical records or imaging studies with which to assess the extent of disease at the time of questionnaire administration. The strong relationship between pain medication use and both PCS and PHQ-9 suggests that physicians treating patients with skull base chordoma should follow patients' pain levels closely and initiate active treatment strategies to adequately control pain after surgical intervention. Multiple studies have found pain to be a determinant of quality of life in patients with cancer. 11, 44, 45, 52, 62 Furthermore, neuropathic pain has a greater effect on quality of life than nociceptive pain. 53 Identification of the type of pain experienced by chordoma patients will be important in achieving improvement in quality of life through pain control. We recommend a careful preoperative pain evaluation, optimal perioperative pain control, and a surveillance strategy for definitive management of new tumor-related pain symptoms as they arise.
Demographic factors did not have much impact on quality of life and functional outcomes, although smoking impacted negatively on role-emotional, social functioning, and general mental health subscales of SF-36. Cigarette smoking was reported in approximately onethird of patients in the study cohort. Negative effects on role-emotional and general mental health subscales of SF-36 have been previously demonstrated in patients who smoke. 49 Furthermore, smoking cessation programs using behavioral modification along with bupropion or nicotine replacement have resulted in improved physical healthand mental health-related quality of life. 49, 61 Therefore, we encourage a comprehensive smoking cessation program in patients with chordoma who are current smokers at the time of diagnosis.
Despite the finding of reduced quality of life in patients with skull base chordoma, we found that caregiver burden was low. The ZBI scores closely resembled those observed for brain tumor patients in a supportive palliative care setting. 27 Furthermore, no demographic or clinical factors were found to be associated with the ZBI score. The estimate of caregiver burden in this study is limited by the small sample of responders and the lack of details about the available supports for the patient and family. Duration of caregiving, coping strategies of caregivers, and the degree of social support are all factors that have previously been associated with caregiver burden.
5,34,57
The major strengths of this study include its extraction of information from an international cohort, the use of multiple HRQOL instruments, and a relatively large sample size given the low prevalence of chordoma. At the same time, we recognize the problems and limitations raised by the website-based questionnaire methodology used in this study. The major limitations include sampling bias, selection bias, inability to calculate exact survey response rate, and potential for problems with data quality. Our study sample may be overrepresented by patients with access to a computer and who have the mental and physical capacity to allow the completion of the website questionnaire. These limitations are reflected in the observation that younger patients (< 30 years) comprise 27% of the study cohort and over half of the patients had a university degree. Furthermore, the study was drawn from only one online support group whose members may differ from non-Internet users and other online or face-toface support group users. As such the study population is a self-selected subgroup of chordoma patients and not a randomly selected sample. We were not able to calculate the response rate for this survey because the exact number of chordoma patients who viewed the request for survey participation was unknown. Given the online-based method of data collection and anonymity of the survey, researchers cannot know exactly who is responding to a survey, and thus the integrity of data may arguably be diminished by misrepresentation of respondent identity or survey responses. Despite these limitations, the study cohort showed characteristics that resemble those of skull base chordoma patients in other clinical studies including mean age at diagnosis, neurological symptoms and signs at presentation, and treatment received. 7, 14, 43 The physical functioning of the patients in this study was reflected by a mean KPS score of 82, which is similar to that reported in the literature for other patients with skull base chordoma (mean KPS score range 69-84). 7, 14, 43, 60 The congruence of the study cohort clinical characteristics with published data supports the external validity of our questionnaire. Internal validity was supported using previously validated functional and quality of life outcome instruments. We note the strong correlations observed between the functional outcome measures (KPS and GOSE) and SF-36 PCS, as well as between depression levels (PHQ-9) and SF-36 MCS, which are expected findings based on the construct validity described for SF-36.
56
Conclusions
In a large cohort of patients with skull base chordomas surveyed online, we have found that the major determinants of quality of life are neurological deficits (senso- ry deficit or bowel/bladder dysfunction), pain medication use, corticosteroid use, and levels of depression as scored by PHQ-9. We recommend specific strategies (Table 6) to address these important factors as part of a comprehensive care program for patients with skull base chordomas.
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